Tacrolimus (TAC)

DRUG10 trials

Conditions

Acute Graft Versus Host DiseaseAcute Lymphocytic LeukemiaAcute Myeloid LeukemiaBiphenotypic/Undifferentiated LeukemiaBurkitt LymphomaChronic Myelogenous LeukemiaGraft vs. Host DiseaseGraft-versus-host Disease (GVHD)

Phase 1

CCFZ533X2201 - PoC Study in de Novo Renal Transplantation

CompletedNCT02217410

Novartis PharmaceuticalsKidney Transplantation

Start: 2015-02-05End: 2017-11-29Updated: 2021-09-28

Phase 2

Graft-Versus-Host Disease (GVHD) Prophylaxis After Allogeneic Peripheral Blood Hematopoietic Cell Transplantation

CompletedNCT00803010

H. Lee Moffitt Cancer Center and Research InstituteAcute Graft Versus Host Disease

Start: 2008-09-30End: 2012-12-31Updated: 2015-07-31

Tacrolimus, Sirolimus and Ustekinumab vs. Tacrolimus and Sirolimus for the Prevention of Acute Graft-Versus-Host Disease

CompletedNCT01713400

H. Lee Moffitt Cancer Center and Research InstituteGraft vs. Host Disease

Start: 2013-02-25End: 2018-06-14Updated: 2020-03-04

Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy

Active, not recruitingNCT03674411

Masonic Cancer Center, University of MinnesotaAcute Lymphocytic Leukemia, Acute Myeloid Leukemia, Biphenotypic/Undifferentiated Leukemia +8

Start: 2019-01-02End: 2026-12-01Updated: 2026-01-06

A Dose Escalation Study in de Novo Renal Transplantation

CompletedNCT04311632

ITB-Med LLCKidney Transplantation

Start: 2021-05-26End: 2023-10-03Updated: 2025-02-27

A Dose Escalation Study of TCD601 Compared to ATG in de Novo Renal Transplantation

TerminatedNCT06365437

ITB-Med LLCKidney Transplantation

Start: 2021-06-06End: 2024-12-11Updated: 2026-03-12

VEL-101 to Prevent Rejection After Kidney Transplantation

Not yet recruitingNCT07290777

Veloxis PharmaceuticalsTransplantation, Kidney

Start: 2026-07-31End: 2028-10-31Target: 120Updated: 2025-12-18

Phase 3

A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)

RecruitingNCT06615050

Incyte CorporationGraft-versus-host Disease (GVHD)

Start: 2025-04-02End: 2031-01-17Target: 572Updated: 2025-12-16

Phase 4

A Trial of Two Steroid-Free Approaches Toward Mycophenolate Mofetil-Based Monotherapy Immunosuppression

TerminatedNCT00166712

Northwestern UniversityKidney Transplant Failure and Rejection

Start: 2005-04-30End: 2010-04-30Updated: 2015-10-26

A Study Investigating the Renal Tolerability, Efficacy, and Safety of a CNI-free Versus a Standard Regimen in de Novo Heart Transplant (HTx) Recipients

CompletedNCT00862979

Novartis PharmaceuticalsHeart Transplantation

Start: 2009-02-24End: 2017-03-06Updated: 2018-08-07

Biology of Blood and Marrow Transplantation2020-01-23

Mgta-456, an Aryl Hydrocarbon Receptor (AHR) Antagonist Based Expansion of CD34+ Hematopoietic Stem Cells (HSC), Permits Selection of Better HLA Matched Cord Blood Units (CBUs) and Promotes Faster Neutrophil Recovery and Uniform Engraftment with Potentially Less Acute Graft-Vs-Host Disease (GVHD)

Blood2019-11-134 citations

CD40 Inhibition with CFZ533 - A New, Fully Human, Non-Depleting, Fc Silent mAB - Improves Renal Allograft Function While Demonstrating Comparable Efficacy vs. Tacrolimus in De-Novo CNI-Free Kidney Transplant Recipients

Transplantation2018-07-019 citations

MANDELA Study Results at 18 Months after Heart Transplantation

Transplantation2018-07-012 citations

IL-12/23p40 Neutralization in Combination with Sirolimus for Prevention of Acute Graft Vs. Host Disease

Biology of Blood and Marrow Transplantation2015-01-22